Observational studyBritish journal of clinical pharmacology2025
Real-world treatment patterns among patients diagnosed with hormone receptor-positive metastatic breast cancer in the USA.
Observational study in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world treatment patterns among patients diagnosed with hormone receptor-positive metastatic breast cancer in the USA.British journal of clinical pharmacology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsClinical guidelines for breast cancer management have evolved in the past decade. However, limited evidence exists regarding uptake of novel drug classes in management of hormone receptor-positive (HR+) metastatic breast cancer (MBC) in the USA and whether disparities exist by race and ethnicity.
methodsUsing SEER-Medicare databases, we identified 4404 women aged ≥66 years diagnosed with HR+ de novo MBC (dnMBC) between 2010 and 2019. Age-standardized rates for receipt of first-line treatment were calculated. Age-adjusted rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using Poisson regression to compare rates among non-Hispanic Black (NHB) and Hispanic patients with non-Hispanic White (NHW) patients.
resultsAmong patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) dnMBC after 2015, 48.6% received first-line treatment with aromatase inhibitors (AIs) and 22.8% with AIs plus cyclin-dependent kinase (CDK) 4/6 inhibitors. Rates for AIs + CDK4/6 inhibitors increased (per 1000 person-years: 262.2 in 2015; 452.8 in 2019). Compared with NHW, NHB (RR [95% CI%]: 0.87 [0.63-1.21]) and Hispanic patients (RR [95% CI%]: 0.74 [0.51-1.08]) were less likely to receive AIs + CDK4/6 inhibitors. For HR+/HER2+ dnMBC, 29.7% of patients received pertuzumab, 23.1% with AIs and 10.8% with AIs + trastuzumab. Rates for pertuzumab increased, while rates for trastuzumab monotherapy declined. Compared with NHW, NHB and Hispanic women were less likely to receive anti-HER therapy (RR [95% CI]: 0.51 [0.35-0.73] and 0.58 [0.39-0.86]).
conclusionThere is a temporal increase in first-line treatment with AIs + CDK4/6 inhibitors and pertuzumab in dnMBC in the USA but with significant disparities by race and ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.